Business Wire

DATAIKU

24.5.2023 11:01:30 CEST | Business Wire | Press release

Share
Dataiku Survey Reveals 84% of Companies Are Using Low- and No-Code Platforms to Achieve AI Goals

According to research run by Dataiku, the platform for Everyday AI, the power of data and AI is becoming increasingly available to non-technical employees at companies across EMEA.

The survey, which was run across the United Kingdom, France, the Netherlands, Germany, and the United Arab Emirates, polled over 700 senior decision makers of companies actively using data science platforms and AI models across the enterprise.

It identified a growing trend of empowered non-technical users working with data and AI to make pivotal business decisions. Forty seven percent of EMEA leaders indicated that their non-technical business users have full access to data and AI to attain business goals, and a further 49% stated that business users have at least some access. Eighty four percent of these companies across EMEA said that they are using low- and no-code platforms to achieve these AI goals.

Dataiku Senior Vice President and General Manager, Gregory Herbert, commented: “We’ve seen a great shift in accessibility via the use of low- and no-code platforms, but for many companies, there’s still extensive untapped potential when it comes to making data and AI available to non-technical business users. What we really want to see is AI that is so ingrained and intertwined with the workings of the day-to-day that it’s just part of the business — not only being used or developed by data scientists. If enterprises want to see a deeper transformation and truly data-driven business results, Everyday AI must become a reality for non-data-focused roles.”

AI Drives Momentum Despite Economic Volatility

The majority of companies (79%) surveyed across EMEA indicated they are leveraging AI to its full capacity, and more than 80% of firms indicated that they are able to measure the ROI of their AI investments.

The survey also indicated continued momentum with AI across EMEA. While leaders indicated that business acceleration (50%) and staying ahead of the competition (36%) were the initial top reasons for investing in AI, 2023 has seen a marked shift in AI business goals. When asked what the top three business goals companies were looking to achieve with AI over the next five years, innovation won out (59%), followed by cost reduction (49%) and increased revenue (48%.)

How Will the European Union’s New AI Regulation Impact Business?

The upcoming EU AI regulation requires that any business that commercialises an AI system as a service or a product on the European market conduct a risk assessment to identify risks for all AI systems across the enterprise. This includes any risk surrounding data quality, transparency, human oversight, and accountability.

While there have been criticisms of the EU AI Act’s potential impact on AI innovation, the survey revealed that nearly 80% of respondents did not feel it would hinder innovation and, rather, would introduce new opportunities.

-ENDS-

About Dataiku

Dataiku is the platform for Everyday AI that allows companies to leverage one central solution to design, deploy, govern, and manage AI and analytics applications. Since its founding in 2013, the company has been the leader in democratizing data and empowering organization-wide collaboration. Today, more than 500 companies worldwide use Dataiku to integrate and streamline their use of data, analytics, and AI, driving diverse use cases from fraud detection and customer churn prevention, to predictive maintenance and supply chain optimization. Stay connected with us on our blog, Twitter (@dataiku) and on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005027/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye